Videos

Multiple Myeloma With Symptomatic Progression

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.

ALK-Translocated Non-Small Cell Lung Cancer With Bone Metastases

Recurrent Metastatic Gastrointestinal Stromal Tumor

High-Risk Primary Myelofibrosis

Hydroxyurea Resistant Polycythemia Vera